434 related articles for article (PubMed ID: 33951326)
1. The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab.
Degens JHRJ; Dingemans AC; Willemsen ACH; Gietema HA; Hurkmans DP; Aerts JG; Hendriks LEL; Schols AMWJ
J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):657-664. PubMed ID: 33951326
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
Degens JHRJ; Sanders KJC; de Jong EEC; Groen HJM; Smit EF; Aerts JG; Schols AMWJ; Dingemans AC
Lung Cancer; 2019 Jul; 133():130-135. PubMed ID: 31200819
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer.
Blanc-Durand P; Campedel L; Mule S; Jegou S; Luciani A; Pigneur F; Itti E
Eur Radiol; 2020 Jun; 30(6):3528-3537. PubMed ID: 32055950
[TBL] [Abstract][Full Text] [Related]
4. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients.
Willemsen ACH; De Moor N; Van Dessel J; Baijens LWJ; Bila M; Hauben E; van den Hout MFCM; Vander Poorten V; Hoeben A; Clement PM; Schols AMWJ
Cancer Med; 2023 Apr; 12(7):7699-7712. PubMed ID: 36484469
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.
Cortellini A; Verna L; Porzio G; Bozzetti F; Palumbo P; Masciocchi C; Cannita K; Parisi A; Brocco D; Tinari N; Ficorella C
Thorac Cancer; 2019 Feb; 10(2):347-351. PubMed ID: 30600905
[TBL] [Abstract][Full Text] [Related]
7. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
Debieuvre D; Juergens RA; Asselain B; Audigier-Valette C; Auliac JB; Barlesi F; Benoit N; Bombaron P; Butts CA; Dixmier A; Gröschel A; Gutz S; Labbé C; Moro-Sibilot D; Pérol M; Raspaud C; Schumann C; Juarez-Garcia A; Lakhdari K; Pettersson F; Penrod JR; Reynaud D; Waldenberger D; Allan V; Sebastian M
Lung Cancer; 2021 Jul; 157():40-47. PubMed ID: 33980420
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
[TBL] [Abstract][Full Text] [Related]
9. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
[TBL] [Abstract][Full Text] [Related]
12. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.
Atlan P; Bayar MA; Lanoy E; Besse B; Planchard D; Ramon J; Raynard B; Antoun S
Support Care Cancer; 2017 Nov; 25(11):3365-3373. PubMed ID: 28593463
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F
Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
15. Effect of adipose tissue volume on prognosis in patients with non-small cell lung cancer.
Lee JW; Lee HS; Na JO; Lee SM
Clin Imaging; 2018; 50():308-313. PubMed ID: 29751203
[TBL] [Abstract][Full Text] [Related]
16. Marked loss of adipose tissue during neoadjuvant therapy as a predictor for poor prognosis in patients with gastric cancer: A retrospective cohort study.
Zhang Y; Li Z; Jiang L; Xue Z; Ma Z; Kang W; Ye X; Liu Y; Jin Z; Yu J
J Hum Nutr Diet; 2021 Jun; 34(3):585-594. PubMed ID: 33491826
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab.
Araki T; Tateishi K; Sonehara K; Hirota S; Komatsu M; Yamamoto M; Kanda S; Kuraishi H; Hanaoka M; Koizumi T
Thorac Cancer; 2021 Mar; 12(5):603-612. PubMed ID: 33434414
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
[TBL] [Abstract][Full Text] [Related]
19. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer.
Imai H; Naito E; Yamaguchi O; Hashimoto K; Iemura H; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
Thorac Cancer; 2022 May; 13(10):1479-1489. PubMed ID: 35394119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
